Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).

It acts as an inhibitor of the zoster virus's helicase–primase complex.[1][2] Amenamevir was approved in Japan for the treatment of shingles in 2017.[3]

See also

References

  1. ^ Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. (November 2017). "Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study". The Journal of Dermatology. 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394.
  2. ^ Yajima M, Yamada H, Takemoto M, Daikoku T, Yoshida Y, Long T, et al. (March 2017). "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor". Antiviral Research. 139: 95–101. doi:10.1016/j.antiviral.2016.12.008. PMID 28027917. S2CID 43813287.
  3. ^ "Maruho Receives Manufacturing and Marketing Approval for Anti-Herpes Virus Agent "Amenalief® Tab. 200mg" in Japan" (Press release). evaluategroup.com. July 3, 2017.


Allikas: https://en.wikipedia.org/wiki/Amenamevir
No tags for this post.